Novel protein, readthrough between PIK3R2 and IFI30 (ENSG00000268173)

This entity corresponds to a readthrough (also known as a fusion) transcript between the PIK3R2 (phosphoinositide-3-kinase regulatory subunit 2) and IFI30 (lysosomal thiol reductase) genes, located on chromosome 19[1][3][5][9][10]. Such readthroughs often arise from transcriptional continuation across adjacent genes and may encode chimeric or uncharacterized proteins. There is minimal evidence for the existence, functional significance, or therapeutic target relevance of the protein product of this transcript in the literature or databases. Consequently, it is not considered a validated therapeutic target. This entry does not correspond to a canonical, well-defined protein with established molecular function, disease relevance, or drug interactions. Neither PIK3R2 nor IFI30, as individual genes, are implicated in this specific fusion as a known drug target or receptor in the usual scientific or therapeutic sense[2][4][8][11][12]. This readthrough transcript is a genomic annotation artifact, and there is insufficient evidence to suggest it is expressed as a functional protein or has any clinical utility. Most sources simply reproduce its annotation as a "novel protein," reinforcing that it is not a correctly defined, actionable biomolecule for therapeutic purposes[1][3][5][9][10]. This entity is not a canonical target and likely represents a mis-annotation or at best a predicted, uncharacterized readthrough product; it is not an actionable receptor, drug target, or well-defined protein for research or medicine.

Other names

AC007192.1